Podcast appearances and mentions of virginia kaklamani

  • 22PODCASTS
  • 44EPISODES
  • 1h 27mAVG DURATION
  • 1EPISODE EVERY OTHER WEEK
  • Apr 8, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about virginia kaklamani

Latest podcast episodes about virginia kaklamani

Hear From Her: The Women in Healthcare Leadership Podcast Series
Collaboration Across Healthcare is the Path Forward

Hear From Her: The Women in Healthcare Leadership Podcast Series

Play Episode Listen Later Apr 8, 2025 25:19


Meet two global healthcare leaders on a mission to improve how the system moves forward for women. Elcin Barker Ergun is CEO of Menarini Group, the largest pharmaceutical company in Italy. Virginia Kaklamani, MD, is professor of medicine, Division of Hematology-Medical Oncology at The University of Texas Health Science Center and leads the breast cancer program at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center. In this episode, they share their personal journeys to leadership positions, and talk about why it's OK to say that men and women are different (and how that benefits women). They also believe that kids growing up now will just expect women to hold leadership roles, in medicine and beyond. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

OncLive® On Air
S12 Ep23: Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc

OncLive® On Air

Play Episode Listen Later Mar 10, 2025 5:27


Dr Kaklamani discusses the mechanism of action of inavolisib, the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm, and considerations for early biomarker testing in patients with breast cancer. 

Oncology Brothers
How to Treat Triple Negative Breast Cancer - Discussion with Dr. Virginia Kaklamani

Oncology Brothers

Play Episode Listen Later Feb 10, 2025 16:50


Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Virginia Kaklamani from the UTHealth San Antonio MD Anderson Cancer Center to discuss the latest advances in the treatment of triple negative breast cancer (TNBC) as we kick off 2025. •⁠  ⁠The treatment paradigms for early-stage TNBC, including the role Sacituzumab and radiation therapy. •⁠  ⁠Insights from the SABCS 2024 conference, focusing on the keynote 522 regimen and its implications for neoadjuvant treatment. •⁠  ⁠The management of locally advanced and metastatic TNBC, including the use of immunotherapy and the importance of PD-L1 testing. •⁠  ⁠Strategies for managing toxicities associated with treatments like sacituzumab and T-DXd. Whether you're a healthcare professional or someone interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! Key Takeaways: •⁠  ⁠Current standard of care for locally advanced TNBC. •⁠  ⁠The significance of chemotherapy and immunotherapy in treatment plans. •⁠  ⁠Managing toxicities in metastatic disease. Stay tuned for more discussions on treatment algorithms, FDA approvals, and clinical pearls in oncology! YouTube: https://youtu.be/GfROoYPVb_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

CCO Oncology Podcast
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

CCO Oncology Podcast

Play Episode Listen Later Jan 9, 2025 36:04


In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium:Estrogen Receptor Mutations in Patients With HR-Positive/HER2-Negative Advanced Breast CancerCurrent Guideline Recommendations for When to Pursue ESR1 Mutation Testing Mutations in Patients With HR-Positive/HER2-Negative Advanced Breast CancerChoice and Sequencing of Next Line of Systemic Therapy for ESR1-Mutated Advanced Breast Cancer Based on Tumor Molecular AlterationsOverview of Class-Related and Unique Adverse Events With Approved and Emerging Oral SERDSExpert Recommendations for the Management of Oral SERDs-Related Adverse EventsProgram faculty:Virginia Kaklamani, MD, DScProfessor of MedicineRuth McLean Bowman Bowers Chair in Breast Cancer Research and TreatmentA.B. Alexander Distinguished Chair in Oncology LeaderBreast Oncology ProgramUT Health San AntonioMD Anderson Cancer CenterSan Antonio, TexasErica L. Mayer, MD, MPHDirector of Breast Cancer Clinical ResearchDana-Farber Cancer InstituteAssociate Professor in MedicineHarvard Medical SchoolBoston, MassachusettsLaura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Resources:To download the slides associated with this podcast discussion, please visit the program page.

Research To Practice | Oncology Videos
Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Jan 3, 2025 120:37


Featuring perspectives from Dr Matthew P Goetz, Dr Sara A Hurvitz, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Seth Wander, including the following topics: Introduction (0:00) Role of CDK4/6 Inhibitors in Hormone Receptor (HR)-Positive Localized Breast Cancer — Dr Hurvitz (12:21) Incorporation of CDK4/6 Inhibitors into the Management of HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Wander (34:36) Evolving Role of PI3K Inhibitors for HR-Positive mBC Harboring PIK3CA Mutations — Dr Goetz (57:58) Clinical Utility of AKT Inhibitors for Patients with Progressive HR-Positive mBC — Dr Jhaveri (1:15:52) Oral SERDs (Selective Estrogen Receptor Degraders) for HR-Positive mBC — Dr Kaklamani (1:37:24) CME information and select publications

Oncology Today with Dr Neil Love
Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer

Oncology Today with Dr Neil Love

Play Episode Listen Later Jan 3, 2025 120:36


Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share their perspectives on the management of hormone receptor-positive breast cancers and the potential role of emerging data from SABCS 2024, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/SABCS2024/HRPosEndocrine).

Breast Cancer Update
Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer

Breast Cancer Update

Play Episode Listen Later Jan 3, 2025 120:36


Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share their perspectives on the management of hormone receptor-positive breast cancers and the potential role of emerging data from SABCS 2024.

Project Oncology®
EMERALD Expert Views: Managing ER+/HER2-, ESR1m mBC Disease Progression Post ET+CDK4/6i

Project Oncology®

Play Episode Listen Later Nov 26, 2024


Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there's uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.

Medical Industry Feature
EMERALD Expert Views: Managing ER+/HER2-, ESR1m mBC Disease Progression Post ET+CDK4/6i

Medical Industry Feature

Play Episode Listen Later Nov 26, 2024


Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there's uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.

Targeted Talks
S5 Ep17: Kaklamani's Insights on EMERALD Trial and Elacestrant in Advanced Breast Cancer

Targeted Talks

Play Episode Listen Later Sep 26, 2024 13:41


In this episode of Targeted Talks, Virginia Kaklamani, MD, DSc, professor of medicine in the Division of Hematology-Medical Oncology at The University of Texas Health Science Center San Antonio and the leader of the breast cancer program at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, discusses the background, findings, and implications of the phase 3 EMERALD trial.

CCO Oncology Podcast
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

CCO Oncology Podcast

Play Episode Listen Later Jul 22, 2024 34:45


In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer.Presenters:Virginia Kaklamani, MD, DScProfessor of MedicineRuth McLean Bowman Bowers Chair in Breast Cancer Research and TreatmentA.B. Alexander Distinguished Chair in Oncology LeaderBreast Oncology ProgramUT Health San AntonioMD Anderson Cancer CenterSan Antonio, TexasAditya Bardia, MD, MPH, FASCOProfessor of MedicineGeffen School of Medicine at UCLADirector, Breast Oncology ProgramAssistant Chief (Translational Research)Division of Medical OncologyDirector of Translational Research IntegrationUCLA Health Jonsson Comprehensive Cancer CenterLos Angeles, CaliforniaSarah Sammons, MDAssistant Professor of MedicineDana-Farber Cancer Institute Harvard Medical SchoolBoston, Massachusetts Link to full program:https://bit.ly/46hLGcM

Research To Practice | Oncology Videos
Breast Cancer | Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Jun 13, 2024 155:29


Featuring perspectives from Dr William J Gradishar, Dr Virginia Kaklamani, Dr Erica Mayer and Dr Seth Wander, including the following topics: Introduction (0:00) Addition of Ovarian Function Suppression (OFS) to Adjuvant Endocrine Therapy for Premenopausal Patients with Hormone Receptor (HR)-Positive Breast Cancer — Dr Gradishar (4:49) Case: A woman in her mid 20s with HR-positive, HER2-positive intraductal carcinoma (IDC) who received ovarian suppression with TAC chemotherapy and concurrent trastuzumab/pertuzumab followed by tamoxifen (30:48) Case: A woman in her late 30s with HR-positive, HER2-negative IDC and no nodal involvement who received postoperative chemoradiation therapy followed by tamoxifen and is considering ovarian suppression (39:31) Role of OFS in Preserving Fertility and/or Ovarian Function in Premenopausal Patients – Dr Mayer (44:55) Case: A woman in her early 30s with HR-positive, HER2-positive (IHC 3+) IDC recommended to receive perioperative TCHP who is interested in fertility preservation (1:11:15) Case: A woman in her mid 30s presenting with ER-positive, HER2-negative breast cancer during early pregnancy who received preoperative TAC and had pathologic complete response at surgery (1:14:18) Tolerability and Toxicity of OFS – Dr Kaklamani (1:21:21) Case: A woman in her mid 30s, uninterested in fertility preservation, who received chemotherapy and TAC followed by tamoxifen and abemaciclib for ER-positive, HER2-negative breast cancer (1:39:42) Case: A premenopausal woman in her late 40s with a 3.6-cm breast tumor and a Recurrence Score (RS) of 26 who becomes amenorrheic with chemotherapy and TC (1:43:32) Other Practical Considerations in the Application of OFS – Dr Wander (1:46:29) Case: A woman in her early 50s with HR-positive, HER2 IHC 2+ invasive lobular carcinoma and a RS of 15 who declined chemotherapy and opted to stop adjuvant leuprolide after 1 year (1:59:56) Case: A woman in her early 40s with HR-positive, HER2 IHC 1+ breast cancer who has no interest in fertility preservation and significant residual disease at surgery (2:14:06) CME information and select publications

Breast Cancer Update
Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer

Breast Cancer Update

Play Episode Listen Later Jun 13, 2024 155:49


Dr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Seth Wander from Massachusetts General Hospital in Boston, discuss key findings and practical considerations with ovarian function suppression for hormone receptor-positive breast cancer.

Oncology Today with Dr Neil Love
Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer

Oncology Today with Dr Neil Love

Play Episode Listen Later Jun 12, 2024 155:49


Dr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Seth Wander from Massachusetts General Hospital in Boston, discuss key findings and practical considerations with ovarian function suppression for hormone receptor-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OvarianSuppressionBCThinkTank).

Research To Practice | Oncology Videos
Metastatic HER2-Positive and Triple-Negative Breast Cancer | Third Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later Apr 19, 2024 48:01


Featuring perspectives from Dr Erika Hamilton, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics. HER2-Positive Metastatic Breast Cancer — Dr Hamilton (0:00) Metastatic Triple-Negative Breast Cancer — Dr Rugo (29:06) SABCS® 2023 Review — Dr Kaklamani (45:20) CME information and select publications

Research To Practice | Oncology Videos
Localized Breast Cancer | Third Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later Apr 19, 2024 50:50


Featuring perspectives from Dr Virginia Kaklamani, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics. Introduction (0:00) Localized HER2-Positive and Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:52) SABCS® 2023 Review — Dr Kaklamani (31:48) Localized ER-Positive Breast Cancer — Dr Kalinsky (38:10) CME information and select publications

Real Pink
Episode 273: Did You Know That Your Tumor Might Change Over Time?

Real Pink

Play Episode Listen Later Apr 8, 2024 12:19


No two breast cancers are the same, and researchers have come a long way in understanding what makes each breast tumor unique. This is the entire premise behind personalized medicine. By looking at a tumor's biomarkers, doctors can tailor their patient's treatment to best fight their unique tumor. On today's show, we'll be discussing biomarkers that doctors look for in breast tumors and how they use them to design a treatment plan. We'll also hear about a new twist on an old biomarker, the estrogen receptor, and how it's being put into clinical practice. Joining us today to share her expertise is Dr. Virginia Kaklamani, M.D. Dr. Kaklamani is a professor of medicine and leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center.

Oncology Brothers
How to Treat HR+ Breast Cancer with Dr. Virginia Kaklamani | Onc Brothers

Oncology Brothers

Play Episode Listen Later Feb 15, 2024 21:02


In discussion with Dr. Virginia Kaklamani, we cover treatment algorithm of HR+ breast cancer. We covered the current standard of care treatment options for HR+ breast cancer.   #HER2 #Sensitive #Breast #Cancer #2024 #oncology #oncbrothers   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Research To Practice | Oncology Videos
HER2-Negative Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Localized HER2-Negative Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Dec 28, 2023 121:47


Featuring perspectives from Prof Francois-Clement Bidard, Dr Erika Hamilton, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics: Introduction (0:00) Role of Genomic Assays in Treatment Decision-Making for Localized ER-Positive, HER2-Negative Breast Cancer — Dr Goetz (6:03) Integration of Ovarian Function Suppression into the Management of Breast Cancer in  Premenopausal Patients — Dr Burstein (33:34) Role of CDK4/6 Inhibitors and Other Novel Agents in Therapy for  ER-Positive Localized Breast Cancer — Dr Hurvitz (52:35) Optimizing the Use of Neoadjuvant and Adjuvant Therapy for Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:16:18) Emerging Role of Circulating Tumor DNA Evaluation in the Management of Breast Cancer — Dr Pusztai (1:42:03) CME information and select publications

Research To Practice | Oncology Videos
ER-Positive Metastatic Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of ER-Positive Metastatic Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Dec 21, 2023 120:27


Featuring perspectives from Prof Francois-Clement Bidard, Dr Erika Hamilton, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics: Introduction (0:00) Optimal Integration of CDK4/6 Inhibitors into the Management of ER-Positive Metastatic Breast Cancer (mBC) — Dr Kaklamani (7:00) Novel Strategies to Overcome Resistance to Endocrine Therapy — Dr Jhaveri (26:20) Current Role of Antibody-Drug Conjugates in the Management of ER-Positive mBC — Dr Rugo (1:00:09) Current and Future Role of Selective Estrogen Receptor Degraders (SERDs) in the Management of ER-Positive mBC — Prof Bidard (1:28:59) Novel Therapies Under Investigation for Patients with ER-Positive mBC — Dr Hamilton (1:40:50) CME information and select publications

Our MBC Life
S07 E08 Understanding Progression: How to Identify & Treat ESR1 Mutations in HR+ MBC

Our MBC Life

Play Episode Listen Later Dec 15, 2023 54:12


New therapeutic options are now available for HR+ MBC.  Dr. Virginia Kaklamani will discuss endocrine therapy resistance, liquid biopsy/blood test, mutations, and treatment sequencing of targeted therapy. You will learn about oral selective estrogen receptor degraders (SERDS), clinical trials, and more. 

OBR Peer-Spectives
ER-Positive Breast Cancer Advances and Other Eagerly Anticipated Data at SABCS 2023

OBR Peer-Spectives

Play Episode Listen Later Nov 20, 2023 11:47


Studies involving high-risk, early-stage ER-positive breast cancer are among the most eagerly anticipated at this year's San Antonio Breast Cancer Symposium (SABCS), to be held Dec. 5-9. Virginia Kaklamani, MD, professor of medicine in the division of hematology and medical oncology at the University of Texas Health Sciences Center San Antonio and leader of the breast cancer program at the Mays Cancer Center, discusses which data she thinks has the best chance of changing practice soon. She also speaks with Bob Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars-Sinai Cancer Center in Los Angeles, about key research into HER2-positive disease, brain metastases, and local therapy to watch for at this year's conference.

Research To Practice | Oncology Videos
What I Tell My Patients: Faculty Physicians and Nurses Discuss the Role of Antibody-Drug Conjugates in the Management of HER2-Expressing Cancers Across the Oncology Spectrum

Research To Practice | Oncology Videos

Play Episode Listen Later Jun 21, 2023 89:03


Featuring perspectives from Dr Lyudmila A Bazhenova, Ms Kelly EH Goodwin, Dr Virginia Kaklamani, Ms Caroline Kuhlman, Ms Alexis N McKinney and Dr Zev Wainberg, including the following topics: Introduction (0:00) HER2 as a Therapeutic Target; Antibody-Drug Conjugates (6:15) HER2-Positive Breast Cancer (23:08) HER2-Positive Gastrointestinal Cancers (46:14) HER2-Positive Non-Small Cell Lung Cancer (1:08:14) Toxicities of Trastuzumab Deruxtecan (1:20:59) NCPD information and select publications

Oncology Brothers
EMERALD Ph III Study in discussion w/ Dr. Virginia Kaklamani (now FDA Approved)

Oncology Brothers

Play Episode Listen Later May 18, 2023 17:10


Discussing the EMERALD Phase III study which resulted in the FDA approval of the first oral selective estrogen receptor degrader (SERD) after demonstrating statistically significant and clinically meaningful benefit in postmenopausal women and men, with ER+, HER2- metastatic breast cancer patients, post progression in first line with endocrine therapy and CDK4/6i. In discussion with Dr. Virginia Kaklamani - Professor of Medicine - Leader of Breast Oncology Program UT Health San Antonio MD Anderson Cancer Center. Website: ⁠⁠http://www.oncbrothers.com/⁠⁠ Twitter: ⁠⁠https://twitter.com/oncbrothers⁠⁠ Contact us at ⁠⁠info@oncbrothers.com⁠

Research To Practice | Oncology Videos
Breast Cancer | What I Tell My Patients: Faculty Physicians and Nurses Discuss Patient Education About New Treatments and Clinical Trials — Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later May 17, 2023 119:13


Featuring perspectives from Ms Jamie Carroll, Dr Virginia Kaklamani, Dr Joyce O'Shaughnessy and Mr Ronald Stein, including the following topics: Introduction (0:00) ER-Positive, HER2-Negative Localized Breast Cancer — Part 1 (7:12) ER-Positive, HER2-Negative Localized Breast Cancer —Part 2 (26:18) ER-Positive Metastatic Breast Cancer (37:16) Localized HER2-Positive Breast Cancer (49:27) HER2-Positive and HER2-Low Metastatic Breast Cancer — Part 1 (1:04:09) HER2-Positive and HER2-Low Metastatic Breast Cancer — Part 2 (1:27:00) PARP Inhibitors (1:32:21) Immune Checkpoint Inhibitors (1:43:32) CME information and select publications

Research To Practice | Oncology Videos
Breast Cancer | Proceedings from a symposium in partnership with NCOA and SCOS

Research To Practice | Oncology Videos

Play Episode Listen Later Mar 17, 2023 59:04


Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Harold Burstein and Virginia Kaklamani on recent advances and real-world implications in breast cancer. CME information and select publications

Hematologic Oncology Update
Recent Advances and Future Directions in Chronic Lymphocytic Leukemia and Lymphomas — With Dr Danielle Brander and Craig Moskowitz (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Hematologic Oncology Update

Play Episode Listen Later Mar 17, 2023 59:32


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

partnership symposium proceedings lymphoma future directions moskowitz brander recent advances chronic lymphocytic leukemia virginia kaklamani ursula matulonis harold burstein daniel petrylak ibiayi dagogo jack rutika mehta south carolina oncology society
Breast Cancer Update
Recent Advances and Future Directions in Breast Cancer — With Dr Harold Burstein and Dr Virginia Kaklamani (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Breast Cancer Update

Play Episode Listen Later Mar 17, 2023 59:03


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

partnership breast cancer symposium proceedings future directions burstein recent advances virginia kaklamani ursula matulonis harold burstein daniel petrylak ibiayi dagogo jack rutika mehta south carolina oncology society
Prostate Cancer Update
Recent Advances and Future Directions in Genitourinary Cancers — With Dr Daniel Petrylak and Dr Sandy Srinivas (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Prostate Cancer Update

Play Episode Listen Later Mar 17, 2023 59:28


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

cancer partnership symposium proceedings future directions srinivas recent advances genitourinary virginia kaklamani ursula matulonis harold burstein daniel petrylak ibiayi dagogo jack rutika mehta south carolina oncology society
Gastrointestinal Cancer Update
Recent Advances and Future Directions in Gastrointestinal Cancers — With Dr Tanios Bekaii-Saab and Dr Rutika Mehta (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Gastrointestinal Cancer Update

Play Episode Listen Later Mar 17, 2023 60:43


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

cancer partnership symposium mehta proceedings saab gastrointestinal future directions recent advances tanios bekaii saab virginia kaklamani ursula matulonis harold burstein daniel petrylak ibiayi dagogo jack rutika mehta south carolina oncology society
Lung Cancer Update
Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Lung Cancer Update

Play Episode Listen Later Mar 17, 2023 59:04


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

partnership symposium proceedings lung cancer future directions recent advances virginia kaklamani ursula matulonis daniel petrylak ibiayi dagogo jack harold burstein rutika mehta south carolina oncology society
Gastrointestinal Cancer Update
Recent Advances and Future Directions in Gastrointestinal Cancers — With Dr Tanios Bekaii-Saab and Dr Rutika Mehta (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Gastrointestinal Cancer Update

Play Episode Listen Later Mar 17, 2023 60:43


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

cancer partnership symposium mehta proceedings saab gastrointestinal future directions recent advances tanios bekaii saab virginia kaklamani ursula matulonis harold burstein daniel petrylak ibiayi dagogo jack rutika mehta south carolina oncology society
Gynecologic Oncology Update
Recent Advances and Future Directions in Gynecologic Cancers — With Dr Michael Birrer and Ursula Matulonis (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Gynecologic Oncology Update

Play Episode Listen Later Mar 17, 2023 63:43


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

partnership symposium proceedings future directions recent advances gynecologic cancers virginia kaklamani ursula matulonis daniel petrylak ibiayi dagogo jack harold burstein rutika mehta south carolina oncology society
Gastrointestinal Cancer Update
Recent Advances and Future Directions in Gastrointestinal Cancers — With Dr Tanios Bekaii-Saab and Dr Rutika Mehta (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Gastrointestinal Cancer Update

Play Episode Listen Later Mar 17, 2023 60:43


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

cancer partnership symposium mehta proceedings saab gastrointestinal future directions recent advances tanios bekaii saab virginia kaklamani ursula matulonis harold burstein daniel petrylak ibiayi dagogo jack rutika mehta south carolina oncology society
Research To Practice | Oncology Videos
ER-Positive Breast Cancer | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Jan 4, 2023 124:40


Featuring perspectives from Drs Aditya Bardia, Matthew Goetz, Virginia Kaklamani, Kevin Kalinsky and Hope Rugo, including the following topics: Current Role of Genomic Assays for Hormone Receptor (HR)-Positive Localized Breast Cancer  Introduction (0:00) Case: A premenopausal woman in her early 40s with 9-mm, Grade III, ER/PR-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC) – 21-gene Recurrence Score® 22 — Alan B Astrow, MD (3:39) Case: A premenopausal woman in her mid 30s with 3.6-cm, ER/PR-positive, HER2-low (IHC 1+), sentinel node-positive (4/4) multifocal IDC after bilateral mastectomies, adjuvant AC-T and ovarian function suppression (OFS)/aromatase inhibitor, Ki67 50% — Laila Agrawal, MD (9:40) Dr Goetz presentation (19:43) Optimizing the Management of Localized ER-Positive Breast Cancer  Case: A woman in her early 40s with 5.5-cm, ER/PR-positive, HER2-negative, node-positive (20/21) IDC after bilateral mastectomies, bilateral salpingo-oophorectomy, adjuvant AC-T and initiation of letrozole/abemaciclib, Ki-67 3% — Susmitha Apuri, MD (32:22) Case: A woman in her mid 50s with de novo ER-positive, PR-negative, HER2-negative ulcerated breast cancer with pulmonary and extensive spinal metastases — Jennifer L Dallas, MD (40:45)  Dr Kaklamani presentation (45:32) Selection and Sequencing of Therapy for Patients with ER-Positive Metastatic Breast Cancer (mBC)  Case: A woman in her early 50s with ER/PR-positive, HER2-low mBC with a PI3KCA mutation who experiences a dramatic response to rechallenge with fulvestrant and a CDK4/6i (abemaciclib); now with progression and cytopenias — Kapisthalam (KS) Kumar, MD (59:07) Dr Kalinsky presentation (1:09:53) Recent Appreciation of HER2 Low as a Unique Subset of HR-Positive Breast Cancer  Case: A premenopausal woman in her late 30s with ER/PR-positive, HER2-low (IHC 1+) IDC after adjuvant tamoxifen and OFS x 5 years, now with bone and liver metastases — Dr Agrawal (1:19:45) Dr Bardia presentation (1:24:29) Novel Strategies Under Investigation for Patients with HR-Positive mBC  Case: A woman in her early 90s with ER/PR-positive, HER2-low (IHC 1+) mBC and progressive disease on multiple lines of endocrine and chemotherapy receives T-DXd — Dr Astrow (1:38:44) Case: A woman in her mid 40s with ER/PR-positive, HER2-low (IHC 2+) mBC who has received fulvestrant/abemaciclib, now receiving exemestane/everolimus – ESR1 and PIK3CA mutations — Dr Dallas (1:44:15) Dr Rugo presentation (1:49:58) CME information and select publications

OBR Peer-Spectives
Matching Breast Cancer Patients to Therapies: Here's How

OBR Peer-Spectives

Play Episode Listen Later Dec 16, 2022 11:00


The landscape for breast cancer treatment is shifting quickly, with an ever-increasingemphasis on targeted and hormonal therapies. Listen as Virginia Kaklamani,MD, professor of medicine in the division of hematology oncology at UT Health San Antonio, and medical directorof the breast oncologyprogram at UT Health San Antonio, MD Anderson Cancer Center,talks with Bob Figlin, MD, Steven Spielberg Family Chair in Hematology-OncologyatCedars-Sinai Cancer,about key findings coming out of the 2022 San Antonio Breast Cancer Symposium. She shares how she'll use elacestrant following updated results from the EMERALD trial, how to select patients for ovarian suppression, and the expanding role of CDK4/6 inhibitors. “[T]here's no role for combination chemotherapy in first-line [estrogen receptor]-positive metastatic breast cancer anymore –even in patients that are deemed to have visceral crisis,”she said.    

Breastcancer.org Podcast
Experimental Elacestrant Seems Effective for Breast Cancer Resistant to Other Types of Hormonal Therapy

Breastcancer.org Podcast

Play Episode Listen Later Dec 8, 2022 8:35


Doctors are looking for new treatment options for people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer that has grown during treatment with hormonal therapy and a CDK4/6 inhibitor. Dr. Virginia Kaklamani is part of the team investigating elacestrant, an oral medicine, to see if offers more benefits than Faslodex (chemical name: fulvestrant), which is the current standard of care. Listen to the podcast to hear Dr. Kaklamani explain: the type of medicine elacestrant is and how it works why it's important that elacestrant showed benefits for breast cancers with an ESR1 mutation when we might hear if elacestrant is approved by the U.S. Food and Drug Administration (FDA)

Breast Cancer Update
Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with ER-Positive Breast Cancer — Part 1 of a 4-Part Series

Breast Cancer Update

Play Episode Listen Later Dec 2, 2021 58:08


Featuring a discussion on the treatment of ER-positive breast cancer with Dr Virginia Kaklamani, moderated by Dr Neil Love.

Research To Practice | Oncology Videos
ER-Positive Breast Cancer | Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with ER-Positive Breast Cancer — Part 1

Research To Practice | Oncology Videos

Play Episode Listen Later Dec 2, 2021 58:15


Featuring perspectives from Dr Virginia Kaklamani, including the following topics: Introduction: Adjuvant Therapy for Breast Cancer — NIH Consensus Statement 2000 (0:00) Case: A premenopausal woman in her early 30s with high-risk localized ER-positive breast cancer — Susmitha Apuri, MD (15:06) Case: A premenopausal woman in her late 40s with localized ER-positive, node-positive breast cancer — Recurrence Score® 14 — Reshma Mahtani, DO (20:22) Case: A premenopausal woman in her mid-40s with localized ER-positive breast cancer — Ruth O'Regan, MD (22:28) Case: A woman in her mid-80s with ER-positive metastatic breast cancer (mBC) — Vikas Malhotra, MD (28:51) Case: A woman in her late 60s with ER-positive mBC — PIK3CA mutation, microsatellite stable, tumor mutation burden 20 mut/Mb — Mamta Choksi, MD (37:36) ESMO 2021 Review (43:20) Case: A woman in her late 50s with ER-positive mBC — PD-L1-negative — Debra Patt, MD, PhD, MBA (50:50) Beyond the Guidelines (53:52) CME information and select publications

Prostate Cancer Update
Up for Debate: Oncology Investigators Provide Their Take on Current Controversies in Patient Care

Prostate Cancer Update

Play Episode Listen Later Jun 18, 2021 301:51


Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Jonathan W Friedberg, Irene M Ghobrial, John V Heymach, Maha Hussain, Virginia Kaklamani, Nancy U Lin, Stephen V Liu, Sagar Lonial, Elizabeth R Plimack and Laurie H Sehn, moderated by Dr Neil Love.

Lung Cancer Update
Up for Debate: Oncology Investigators Provide Their Take on Current Controversies in Patient Care

Lung Cancer Update

Play Episode Listen Later Jun 18, 2021 301:51


Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Jonathan W Friedberg, Irene M Ghobrial, John V Heymach, Maha Hussain, Virginia Kaklamani, Nancy U Lin, Stephen V Liu, Sagar Lonial, Elizabeth R Plimack and Laurie H Sehn, moderated by Dr Neil Love.

Hematologic Oncology Update
Up for Debate: Oncology Investigators Provide Their Take on Current Controversies in Patient Care

Hematologic Oncology Update

Play Episode Listen Later Jun 18, 2021 301:51


Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Jonathan W Friedberg, Irene M Ghobrial, John V Heymach, Maha Hussain, Virginia Kaklamani, Nancy U Lin, Stephen V Liu, Sagar Lonial, Elizabeth R Plimack and Laurie H Sehn, moderated by Dr Neil Love.

Breast Cancer Update
Up for Debate: Oncology Investigators Provide Their Take on Current Controversies in Patient Care

Breast Cancer Update

Play Episode Listen Later Jun 18, 2021 301:51


Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Jonathan W Friedberg, Irene M Ghobrial, John V Heymach, Maha Hussain, Virginia Kaklamani, Nancy U Lin, Stephen V Liu, Sagar Lonial, Elizabeth R Plimack and Laurie H Sehn, moderated by Dr Neil Love.

Caris Molecular Minute Podcast Series
Interview with Dr. Virginia Kaklamani: Breast Cancer and Patient Care

Caris Molecular Minute Podcast Series

Play Episode Listen Later Oct 21, 2020 22:57


Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Virginia Kaklamani from the University of Texas Health San Antonio, to discuss changes in the approach to both metastatic breast cancer and early stage breast cancer, and how these changes are impacting patient care. For more information, please visit: www.CarisLifeSciences.com